HEMATOLOGY_MIDTERMS MedBlock 1st sem,
2013-14
MSV007Series2013
POLYCYTHEMIA CHRONIC ESSENTIAL CHRONIC ACUTE ACUTE CHRONIC
VERA IDIOPATHIC THROMBOCYTOSI MYELOGENOUS MYELOID LYMPHOBLASTIC LYMPHOID
MYELOFIBROSIS S LEUKEMIA LEUKEMIA LEUKEMIA LEUKEMIA
Increase circulating Myelofibrosis with Increased circulating Increased IMMATURE Neoplastic IMMATURE Small MATURE
RBC WITHOUT myeloid metaplasia platelets WITHOUT WBC IMMATURE lymphocytes appearing
recognizable stimulus Extramedullary recognizable cause Ch t(9;22) hematopoietic cells in lymphocytes
*Increase RBC mass hematopoiesis the blood R/t TRISOMY 12
*Normal O2 sat
*SPLENOMEGALY – SPLENOMEGALY SPLENOMEGALY SPLENOMEGALY SPLENOMEGALY SPLENOMEGALY
for sequestration of TEARDROP SHAPE red GINGIVAL, SKIN SPLENOMEGALY
blood cells causing cells, nucleated red INFILTRATION in SMUDGE/BASKET
hyperuricemia cells, myelocytes subtype M4 and M5 CELLS
CD34 cells M0 – CD13,CD33
markedly increased Blasts: M3 – AUER RODS Spec Sens
chronic <10 B CD79 CD19
Accelerat 10-20
in FAGGOT cells CD20
M4,M5 – MONOCYTIC
d T CD3 CD7
Blast >20 M7 – CD61, CD41,
MEGAkaryocytic
lineage, in DOWN
syndrome
CIGARETTE SMOKING FAB >/= 30%
–acceleration to blast WHO >/=20% WHO>/=20% blast
crisis
RADIATION
+ MYELOPEROXIDASE -MYELOPEROXISAE
+SUDAN -SUDAN
+PAS
Complications:
ERYTHROMELALGIA – ANEMIA – treat with
unknown etiology PYRIDOXINE
involving the lower INFECTION (lungs)
extremities:
responsive to
SALICYLATES.
IFN <50y/o IFN IFN IFN Cytarabine INTRATHECAL RICHTER
Hydroxyurea 50-70 Hydroxyurea Hydroxyurea Hydroxyurea Allogenic SCT – Therapy – CNS
Busulfan >70 Glucocorticoids Aminocaproate – for Tretinoin (may cause syndrome –
ALLOGENIC SCT – sanctuary of leukemic
bleeding associated RETINOIC ACID prolymphocytic
only curative cells
Allopurinol – to treat Allopurinol with trhombocytosis SYNDROME) transformation, or
hyperuricemia BMT in young IMATINIB – may transformation to
ANAGRELIDE achieve hematologic or diffuse large B cell
secondary to high cell Splenectomy 7-3 CYTA-DAUNO
cytogenetic remission. lymphoma,
turn-over regimen
Chemotherapy
HEMATOLOGY_MIDTERMS MedBlock 1st sem,
2013-14
MSV007Series2013
splenectomy
BULLET RECALL
Cytochemical stain reacting with lymphoid cells PAS
Treatment for essential thrombocytopenia ANAGRELIDE
Implicated to be the accelerator to blastic phase in CML CIGARETTE SMOKING
Most common presentation of myeloproliferative disorders (MPD) SPLENOMEGALY
Cytogenetic hallmark of CML t(9;22) PHILADELPHIA chromosome
Small mature appearing lymphocytes are present in CLL
With gingival or skin infiltration AML (FAB class M4, M5)
Induces remission in CML IMATINIB
WHO cut-off for CML 20%
With sensitive markers CD19 and CD20 ALL
Treatment of erythromelalgia SALICYLATES
Auer rods in cytoplasm of promyelocyte (FAGGOT CELLS) M3 of AML
FAB cut off for CML 30%
Level of myelobasts in accelerated phase in CML 10-20
Retinoic acid syndrome First 3 weeks of treatment of promyelocytic leukemia (Tretinoin)
Fever, dyspnea, chest pain, pulmonary infiltrates, effusion, hypoxia
Adhesion of differentiated neoplastic cells to pulmonary vasculature
Tx: Clucocorticois and chemotherapy
TEARDROP shaped red cells CIM
Intrathecal chemoprophylaxis is indicated ALL
CML staging: Blasts of >12%, platelet of 80,000 ACCELERATED PHASE
Primary polycythemia vera LOW or UNDETECTED EPO
Secondary polycythemia HIGH EPO
FAB classification of CML most commonly found in down’s syndrome M7
BASKET Cells CLL
RICHTER TRANSFORMATION may develop from… CLL
Triad of myeloma M component, lytic lesion on xray, plasmacytosis >10%
Best regimen for highly aggressive Hodgkin’s lymphoma ABVD/MOPP
Best diagnostic tool in myeloma B2 MICROGLOBULIN
Treatment in multiple myeloma with anti-angiogenic effect MELPHALAN
Lab findings in myeloma Increased calcium, creatinine, plasmacytosis >30%
Most common circulating cells in myeloma PLASMA CELLS
Most common symptom of myeloma BONE PAIN
HEMATOLOGY_MIDTERMS MedBlock 1st sem,
2013-14
MSV007Series2013
With REED-STERNBERG cells HODGKIN’s LYMPHOMA
